Vanguard Capital Management’s Aprea Therapeutics APRE Stock Holding History
Bought
Maintained
Sold
Other funds holding APRE
ACM
Vanguard Capital Management's APRE Position: Q3 2026 in Review
Vanguard Capital Management increased its Aprea Therapeutics (APRE) stake by 115% in Q3 2026, buying an estimated $19.1K and bringing the position to 49,212 shares worth $36.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3936.
Vanguard Capital Management first reported a position in APRE in Q1 2026 and has held it in 3 quarters since. 27 funds tracked by Wall St. Rank hold APRE as of Q3 2026.
- Vanguard Capital Management held 49,212 shares of Aprea Therapeutics worth $36.9K as of Q3 2026.
- Vanguard Capital Management bought 26,330 Aprea Therapeutics shares in Q3 2026, an estimated $19.1K.
- Aprea Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3936 holding.
- Vanguard Capital Management first reported a position in Aprea Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 27 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.